Cargando…
Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611373/ https://www.ncbi.nlm.nih.gov/pubmed/36297505 http://dx.doi.org/10.3390/pharmaceutics14102070 |
_version_ | 1784819509878587392 |
---|---|
author | Jin, Zhiyu Han, Yu Zhang, Danshen Li, Zhongqiu Jing, Yongshuai Hu, Beibei Sun, Shiguo |
author_facet | Jin, Zhiyu Han, Yu Zhang, Danshen Li, Zhongqiu Jing, Yongshuai Hu, Beibei Sun, Shiguo |
author_sort | Jin, Zhiyu |
collection | PubMed |
description | As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients. |
format | Online Article Text |
id | pubmed-9611373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96113732022-10-28 Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients Jin, Zhiyu Han, Yu Zhang, Danshen Li, Zhongqiu Jing, Yongshuai Hu, Beibei Sun, Shiguo Pharmaceutics Review As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients. MDPI 2022-09-28 /pmc/articles/PMC9611373/ /pubmed/36297505 http://dx.doi.org/10.3390/pharmaceutics14102070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jin, Zhiyu Han, Yu Zhang, Danshen Li, Zhongqiu Jing, Yongshuai Hu, Beibei Sun, Shiguo Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title | Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title_full | Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title_fullStr | Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title_full_unstemmed | Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title_short | Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients |
title_sort | application of intranasal administration in the delivery of antidepressant active ingredients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611373/ https://www.ncbi.nlm.nih.gov/pubmed/36297505 http://dx.doi.org/10.3390/pharmaceutics14102070 |
work_keys_str_mv | AT jinzhiyu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT hanyu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT zhangdanshen applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT lizhongqiu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT jingyongshuai applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT hubeibei applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients AT sunshiguo applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients |